dual antiplatelet therapy

El ticagrelor muestra beneficios en la función microvascular coronaria luego de un IAMSEST

Secondary Prevention with P2Y12 Inhibitors: How Consolidated Is This Long Term Alternative vs. Aspirin?

Secondary prevention with P2Y12 inhibitors vs aspirin monotherapy in CAD patients Antiaggregation therapy plays a central role at long term to prevent new cardiovascular events in atherosclerosis patients.&nbsp; After repeat myocardial infarction (MI) or stroke, prognosis can vary considerably. Even though the current guidelines prefer aspirin as the first choice for secondary prevention over P2Y12<a href="https://solaci.org/en/2023/07/13/secondary-prevention-with-p2y12-inhibitors-how-consolidated-is-this-long-term-alternative-vs-aspirin/" title="Read more" >...</a>

Abbreviated Antiaggregant Treatment in High Bleeding Risk Patients from the MASTER-DAPT (15-Month Followup)

Benefits of abbreviated antiaggregant treatment in high bleeding risk patients.&nbsp; Dual antiplatelet therapy (DAPT), established by different guidelines, reduces the risk of ischemic events at the expense of increased bleeding. This habitual APT strategy cannot be applied to patients at high risk of bleeding, which is why this populations are treated with shorter DAPT schemes<a href="https://solaci.org/en/2023/05/15/abbreviated-antiaggregant-treatment-in-high-bleeding-risk-patients-from-the-master-dapt-15-month-followup/" title="Read more" >...</a>

The most read scientific articles in interventional cardiology in February on our website

Below, we share February&#8217;s most read scientific abstracts in interventional cardiology at solaci.org. Can Drug Coated Balloon Be a Valid Option for Small Vessels? One of the challenges of percutaneous coronary interventions (PCI) are &lt;2.5 mm vessels, since complications and restenosis complications rate are higher than with &gt;3.0 mm vessels.&nbsp;&nbsp; Is Using Drug-Eluting Balloons and<a href="https://solaci.org/en/2023/03/22/the-most-read-scientific-articles-in-interventional-cardiology-in-february-on-our-website/" title="Read more" >...</a>

COMPASS: un nuevo lugar para el rivaroxaban en cardiopatía isquémica crónica

Rivaroxaban in Acute Coronary Syndrome

Acute coronary syndromes (ACS) involve high mortality risk, especially ST elevation ACS. Their treatment is based on reperfusion, dual antiplatelet therapy (DAPT) and anticoagulation, with enoxaparin (1 mg/kg twice a day) as the preferred anticoagulant according to the contemporary guidelines.&nbsp; 2.5 mg or 5 mg doses of rivaroxaban might be valid alternative treatments for this<a href="https://solaci.org/en/2023/02/23/rivaroxaban-in-acute-coronary-syndrome/" title="Read more" >...</a>

Diabetes y enfermedad vascular periférica: viejas drogas con nueva evidencia

Is it Possible to Reduce DAPT Time in Diabetic Patients?

Short-duration dual antiplatelet therapy (DAPT) after percutaneous coronary intervention (PCI) with DES is growing steadily, especially for chronic coronary syndromes. There is also some evidence regarding its use in acute coronary syndrome. However, diabetes is a well-known risk factor for both restenosis and thrombosis, since it involves more complex and longer lesions in vessels that<a href="https://solaci.org/en/2023/01/18/is-it-possible-to-reduce-dapt-time-in-diabetic-patients/" title="Read more" >...</a>

The most important articles of 2022 in coronary disease

The Most Important Articles of 2022 in Coronary disease

Discover the most important scientific articles of 2022on coronary disease in our website. An Abbreviated Dual Antiplatelet Regimen Is Also Safe in Patients at High Risk for Bleeding Undergoing Complex Angioplasty The&nbsp;MASTER DAPT&nbsp;study analyzed the results of an&nbsp;abbreviated&nbsp;(mean 34 days) vs. conventional&nbsp;dual antiplatelet therapy (DAPT)&nbsp;in&nbsp;4579 patients treated with angioplasty and a biodegradable polymer sirolimus-eluting stent.<a href="https://solaci.org/en/2023/01/13/the-most-important-articles-of-2022-in-structural-heart-disease-2/" title="Read more" >...</a>

Can We Use DAPT for 3 Months in Acute Coronary Syndrome?

Current guidelines recommend 12-month dual antiplatelet therapy (DAPT) after DES stenting for acute coronary syndrome (ACS) because of elevated MACE risk.&nbsp; The development of more modern stents, with thin and ultrathin struts, compared against prior versions, has resulted in more effective devices in terms of stent thrombosis and restenosis.&nbsp; Prolonged DAPT has been associated with<a href="https://solaci.org/en/2023/01/12/can-we-use-dapt-for-3-months-in-acute-coronary-syndrome/" title="Read more" >...</a>

Anillos aórticos pequeños, ¿Qué válvula deberíamos elegir?

Clinical Implications of the Presence of HALT in TAVR Patients: 5-Year Follow-Up

The duration of percutaneous aortic valve implants can be increasingly observed over time, regardless of their corresponding surgical risk. In the follow-up of different registries, the presence of subclinical valvular thrombosis, evidenced in tomographic studies as an increase in valvular thickness with hypoattenuation (a term known as HALT), was observed from protocolized images.&nbsp; This subclinical<a href="https://solaci.org/en/2023/01/03/clinical-implications-of-the-presence-of-halt-in-tavr-patients-5-year-follow-up/" title="Read more" >...</a>

La reparación de la válvula mitral con Mitraclip es segura en pacientes de alto riesgo

Is the PASCAL Device Effective against MitraClip?

Mitral regurgitation (MR) is the most common valvulopathy and full medical treatment at maximal tolerated doses has been shown quite effective to treat it. However, its limited in a group of patients that require valve intervention.&nbsp; At present, the ideal treatment is surgical valve replacement, which is in many cases is not viable because of<a href="https://solaci.org/en/2022/12/30/is-the-pascal-device-effective-against-mitraclip/" title="Read more" >...</a>

perforación coronaria en angioplastia

We Should Treat Significant Stable CAD in Patients Undergoing TAVR

Aortic stenosis is associated to significant coronary artery disease (CAD) in nearly 50% of cases.&nbsp; When we decide to treat aortic disease using surgery, it has been established we should also treat heart disease.&nbsp; However, when using transcatheter aortic valve replacement (TAVR), this is still unclear, given that in many occasions we see stable lesions<a href="https://solaci.org/en/2022/12/30/we-should-treat-significant-stable-cad-in-patients-undergoing-tavr/" title="Read more" >...</a>

Top